Skip to the reading
KLOW Ordinary

KLOW peptide dosage remains an unanswered human question.

A number from a study can look like the answer you came for. With KLOW, the important question is whether that study tested the same mixture. The papers below didn’t.

What one study actually administered

In Ruff’s 2010 safety trial, healthy volunteers received full-length thymosin beta-4 into a vein. The researchers used 42, 140, 420 or 1,260 mg in single-dose and repeated-dose groups. Those were experimental study amounts for that protein, not KLOW instructions.

Intravenous means into a vein. That route and the exact substance are part of what the researchers tested. Changing either one changes the question the study can answer.

TB-500 is a short piece of thymosin beta-4. It isn’t the full protein used in the trial. The trial’s amounts can’t establish a TB-500 regimen, or a regimen for that fragment mixed with three other ingredients.

The skin route changes the question

Some GHK-Cu research uses a topical preparation, meaning one applied on the skin. A lab study of human skin samples measured copper passing through and staying within the skin. It didn’t test injections or the KLOW blend.

There is no FDA-approved KLOW product label with a human dosing regimen. No controlled study has tested the four-part blend. Adding together amounts from separate ingredient studies doesn’t create a validated schedule.

A preparation’s total contents tell you what is present. They don’t tell you what amount fits a person. That missing evidence can’t be replaced by a conversion or a mixing calculation.

A prescription needs a decision

Useful questions for a clinician include: what evidence supports this preparation for this problem? How would benefit and unwanted effects be assessed? The answers depend on the person as well as the proposed treatment.

The FDA explains that compounded medicines receive no premarket review for safety, effectiveness or quality. A prescription is a clinical decision. It doesn’t supply the blend evidence that the ingredient studies lack.